459 related articles for article (PubMed ID: 30982889)
1. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
[TBL] [Abstract][Full Text] [Related]
2. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
[TBL] [Abstract][Full Text] [Related]
3. Computational design of anti-CRISPR proteins with improved inhibition potency.
Mathony J; Harteveld Z; Schmelas C; Upmeier Zu Belzen J; Aschenbrenner S; Sun W; Hoffmann MD; Stengl C; Scheck A; Georgeon S; Rosset S; Wang Y; Grimm D; Eils R; Correia BE; Niopek D
Nat Chem Biol; 2020 Jul; 16(7):725-730. PubMed ID: 32284602
[TBL] [Abstract][Full Text] [Related]
4. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type IIC Anti-CRISPR Proteins.
Zhu Y; Gao A; Zhan Q; Wang Y; Feng H; Liu S; Gao G; Serganov A; Gao P
Mol Cell; 2019 Apr; 74(2):296-309.e7. PubMed ID: 30850331
[TBL] [Abstract][Full Text] [Related]
5. Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins.
Lee J; Mou H; Ibraheim R; Liang SQ; Liu P; Xue W; Sontheimer EJ
RNA; 2019 Nov; 25(11):1421-1431. PubMed ID: 31439808
[TBL] [Abstract][Full Text] [Related]
6. Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein.
Hoffmann MD; Mathony J; Upmeier Zu Belzen J; Harteveld Z; Aschenbrenner S; Stengl C; Grimm D; Correia BE; Eils R; Niopek D
Nucleic Acids Res; 2021 Mar; 49(5):e29. PubMed ID: 33330940
[TBL] [Abstract][Full Text] [Related]
7. Cell-Type-Specific CRISPR Activation with MicroRNA-Responsive AcrllA4 Switch.
Hirosawa M; Fujita Y; Saito H
ACS Synth Biol; 2019 Jul; 8(7):1575-1582. PubMed ID: 31268303
[TBL] [Abstract][Full Text] [Related]
8. Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.
Jain S; Xun G; Abesteh S; Ho S; Lingamaneni M; Martin TA; Tasan I; Yang C; Zhao H
ACS Synth Biol; 2021 Jun; 10(6):1320-1327. PubMed ID: 34006094
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
10. Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch.
Hirosawa M; Fujita Y; Parr CJC; Hayashi K; Kashida S; Hotta A; Woltjen K; Saito H
Nucleic Acids Res; 2017 Jul; 45(13):e118. PubMed ID: 28525578
[TBL] [Abstract][Full Text] [Related]
11. Coupling Cas9 to artificial inhibitory domains enhances CRISPR-Cas9 target specificity.
Aschenbrenner S; Kallenberger SM; Hoffmann MD; Huck A; Eils R; Niopek D
Sci Adv; 2020 Feb; 6(6):eaay0187. PubMed ID: 32076642
[TBL] [Abstract][Full Text] [Related]
12. Solution structure and dynamics of anti-CRISPR AcrIIA4, the Cas9 inhibitor.
Kim I; Jeong M; Ka D; Han M; Kim NK; Bae E; Suh JY
Sci Rep; 2018 Mar; 8(1):3883. PubMed ID: 29497118
[TBL] [Abstract][Full Text] [Related]
13. Anti-CRISPR AcrIIC3 discriminates between Cas9 orthologs via targeting the variable surface of the HNH nuclease domain.
Kim Y; Lee SJ; Yoon HJ; Kim NK; Lee BJ; Suh JY
FEBS J; 2019 Dec; 286(23):4661-4674. PubMed ID: 31389128
[TBL] [Abstract][Full Text] [Related]
14. A Single-Chain Photoswitchable CRISPR-Cas9 Architecture for Light-Inducible Gene Editing and Transcription.
Zhou XX; Zou X; Chung HK; Gao Y; Liu Y; Qi LS; Lin MZ
ACS Chem Biol; 2018 Feb; 13(2):443-448. PubMed ID: 28938067
[TBL] [Abstract][Full Text] [Related]
15. Strong and tunable anti-CRISPR/Cas activities in plants.
Calvache C; Vazquez-Vilar M; Selma S; Uranga M; Fernández-Del-Carmen A; Daròs JA; Orzáez D
Plant Biotechnol J; 2022 Feb; 20(2):399-408. PubMed ID: 34632687
[TBL] [Abstract][Full Text] [Related]
16. A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy.
Matsumoto D; Tamamura H; Nomura W
Commun Biol; 2020 Oct; 3(1):601. PubMed ID: 33097793
[TBL] [Abstract][Full Text] [Related]
17. Naturally Occurring Off-Switches for CRISPR-Cas9.
Pawluk A; Amrani N; Zhang Y; Garcia B; Hidalgo-Reyes Y; Lee J; Edraki A; Shah M; Sontheimer EJ; Maxwell KL; Davidson AR
Cell; 2016 Dec; 167(7):1829-1838.e9. PubMed ID: 27984730
[TBL] [Abstract][Full Text] [Related]
18. Allosteric inhibition of CRISPR-Cas9 by bacteriophage-derived peptides.
Cui YR; Wang SJ; Chen J; Li J; Chen W; Wang S; Meng B; Zhu W; Zhang Z; Yang B; Jiang B; Yang G; Ma P; Liu J
Genome Biol; 2020 Feb; 21(1):51. PubMed ID: 32102684
[TBL] [Abstract][Full Text] [Related]
19. Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing.
Garcia B; Lee J; Edraki A; Hidalgo-Reyes Y; Erwood S; Mir A; Trost CN; Seroussi U; Stanley SY; Cohn RD; Claycomb JM; Sontheimer EJ; Maxwell KL; Davidson AR
Cell Rep; 2019 Nov; 29(7):1739-1746.e5. PubMed ID: 31722192
[TBL] [Abstract][Full Text] [Related]
20. Engineered anti-CRISPR proteins for optogenetic control of CRISPR-Cas9.
Bubeck F; Hoffmann MD; Harteveld Z; Aschenbrenner S; Bietz A; Waldhauer MC; Börner K; Fakhiri J; Schmelas C; Dietz L; Grimm D; Correia BE; Eils R; Niopek D
Nat Methods; 2018 Nov; 15(11):924-927. PubMed ID: 30377362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
